Watson introduces new oral contraceptive, Vestura

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Pharma, Inc. has launched Vestura(TM) (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer HealthCare Pharmaceuticals Inc.'s Yaz(R) oral contraceptive product.  Watson began shipping the product today. Watson's Vestura(TM) is indicated for the prevention of pregnancy and for the treatment of moderate acne in women at least 14 years old only if the patient desires an oral contraceptive for birth control.

Yaz(R) and its generic versions had total U.S. sales of approximately $510 million for the twelve months ending November 30, 2011, according to IMS Health.